Tirzepatide vs Semaglutide for Obesity: The SURMOUNT-5 Head-to-Head Trial

Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produces greater weight loss, establishing dual agonism superiority.

Aronne, Louis J et al.·The New England journal of medicine·2025·Strong EvidenceRCT
RPEP-09982RCTStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Strong Evidence
Sample
N=not specified
Participants
Adults with obesity without type 2 diabetes

What This Study Found

Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produces greater weight loss, establishing dual agonism superiority.

Key Numbers

1:1 randomization. Tirzepatide max tolerated: 10 or 15 mg. Semaglutide max tolerated: 1.7 or 2.4 mg. Both subcutaneous weekly.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produc
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Published In:
The New England journal of medicine, 393(1), 26-36 (2025)
Database ID:
RPEP-09982

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produces greater weight loss, establishing dual agonism superiority.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09982·https://rethinkpeptides.com/research/RPEP-09982

APA

Aronne, Louis J; Horn, Deborah Bade; le Roux, Carel W; Ho, Wayne; Falcon, Beverly L; Gomez Valderas, Elisa; Das, Sagar; Lee, Clare J; Glass, Leonard C; Senyucel, Cagri; Dunn, Julia P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. The New England journal of medicine, 393(1), 26-36. https://doi.org/10.1056/NEJMoa2416394

MLA

Aronne, Louis J, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.." The New England journal of medicine, 2025. https://doi.org/10.1056/NEJMoa2416394

RethinkPeptides

RethinkPeptides Research Database. "Tirzepatide as Compared with Semaglutide for the Treatment o..." RPEP-09982. Retrieved from https://rethinkpeptides.com/research/aronne-2025-tirzepatide-as-compared-with

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.